BridgeBio Oncology Therapeutics (BBOT) Free Cash Flow (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Free Cash Flow of -$35.9 million for Q1 2026, up 15.32% sequentially from -$42.4 million in Q4 2025, and down 83.09% YoY from -$212.6 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Free Cash Flow (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Free Cash Flow for 3 years, with the latest figure at -$35.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 83.09% year-over-year to -$35.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.4 million (down 76.16% YoY) and the FY2025 annual result came in at -$114.5 million, down 107.89% from the prior year.
- Free Cash Flow grew to -$35.9 million in Q1 2026 per BBOT's latest filing, from -$42.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $18.6 million in Q2 2025 and troughed at -$70.6 million in Q3 2025.
- A 3-year average of -$22.8 million and a median of -$19.6 million in 2025 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 63901.0% in 2025, down 3076.38% in 2025.
- Over 3 years, Free Cash Flow stood at -$15.0 million in 2024, then sank by 182.1% to -$42.4 million in 2025, then increased by 15.32% to -$35.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$35.9 million, -$42.4 million, and -$70.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -45.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.92 Mn |
| Jun 30, 2026 | -45.92 Mn |
| Mar 31, 2026 | -35.94 Mn |
| Mar 31, 2026 | -35.94 Mn |
| Dec 31, 2025 | -42.44 Mn |
| Dec 31, 2025 | -42.44 Mn |
| Sep 30, 2025 | -70.63 Mn |
| Sep 30, 2025 | -70.63 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Mar 31, 2025 | -19.63 Mn |
| Mar 31, 2025 | -19.63 Mn |
| Dec 31, 2024 | -15.05 Mn |
| Dec 31, 2024 | -15.05 Mn |
| Sep 30, 2024 | -39.34 Mn |
| Sep 30, 2024 | -39.34 Mn |
| Jun 30, 2024 | -29,099.00 |
| Jun 30, 2024 | -29,099.00 |
| Mar 31, 2024 | -617,999.00 |
| Mar 31, 2024 | -617,999.00 |